ChengDa Pharmaceuticals Co. Ltd. Market Cap ($539.95 Million)
Market Cap & Net Worth: ChengDa Pharmaceuticals Co. Ltd. (301201)
ChengDa Pharmaceuticals Co. Ltd. market cap. ChengDa Pharmaceuticals Co. Ltd. (SHE:301201) has a market capitalization of $539.95 Million (CN¥3.69 Billion) as of November 6, 2026. Listed on the SHE stock exchange, this China-based company holds position #11527 globally and #3214 in its home market, demonstrating a -0.67% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ChengDa Pharmaceuticals Co. Ltd.'s stock price CN¥23.85 by its total outstanding shares 154713824 (154.71 Million). Also see 301201 operating cash flow for how efficiently the company converts equity into cash flow.
ChengDa Pharmaceuticals Co. Ltd. Market Cap History (2022–2026)
ChengDa Pharmaceuticals Co. Ltd. market cap history from 2022 to 2026. Data shows change from $702.65 Million to $539.95 Million (-21.92% CAGR). Check 301201 live share price for real-time trading data and today's change.
ChengDa Pharmaceuticals Co. Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ChengDa Pharmaceuticals Co. Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 301201 year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.27x
ChengDa Pharmaceuticals Co. Ltd.'s market cap is 2.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $702.65 Million | $411.46 Million | $106.48 Million | 1.71x | 6.60x |
| 2023 | $569.33 Million | $414.30 Million | $90.98 Million | 1.37x | 6.26x |
| 2024 | $456.87 Million | $333.13 Million | -$28.10 Million | 1.37x | N/A |
| 2025 | $921.43 Million | $406.37 Million | -$11.93 Million | 2.27x | N/A |
Competitor Companies of 301201 by Market Capitalization
Companies near ChengDa Pharmaceuticals Co. Ltd. in the global market cap rankings as of November 6, 2026. Also see ChengDa Pharmaceuticals Co. Ltd. assets under control for a full breakdown of the balance sheet.
Key companies related to ChengDa Pharmaceuticals Co. Ltd. by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of ChengDa Pharmaceuticals Co. Ltd. (2022–2026)
Market capitalization of ChengDa Pharmaceuticals Co. Ltd. from 2022 to today. Between 2022 and today, ChengDa Pharmaceuticals Co. Ltd.'s market cap moved from $702.65 Million to $ 539.95 Million, with a yearly change of -21.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥539.95 Million | -41.40% |
| 2025 | CN¥921.43 Million | +101.68% |
| 2024 | CN¥456.87 Million | -19.75% |
| 2023 | CN¥569.33 Million | -18.97% |
| 2022 | CN¥702.65 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of ChengDa Pharmaceuticals Co. Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $539.95 Million USD |
| MoneyControl | $539.95 Million USD |
| MarketWatch | $539.95 Million USD |
| marketcap.company | $539.95 Million USD |
| Reuters | $539.95 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ChengDa Pharmaceuticals Co. Ltd.
ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients, and food and feed additives in China and internationally. It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and A… Read more